The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- Electrical therapy shows promise for metastatic pancreatic cancer
- Outcomes of hematopoietic stem cell transplantation in patients aged 70 years and older
- Glioblastoma treatment GLIX1 enters human trials
- Groundbreaking Results Shift Treatment Paradigm in High-Risk Smoldering Multiple Myeloma
- Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis
- FDA fast tracks treatment for advanced, resistant ovarian cancer
- Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
- Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
- Development and multinational validation of a multiple myeloma–specific comorbidity index using real-world cohorts: CAREMM-2108
- Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy